European Medicines Agency (EMA)

European Medicines Agency reduces clinical trial secrecy

The EMA has made a landmark policy move that will see it publish the clinical trial reports underpinning a medicine’s licence.…

Cancer drugs approved faster in the United States than in Europe or Canada

Regulatory agencies in the United States take less time to approve new cancer drugs than those in Europe or Canada, according to new research.…

European Medicines Agency to review Ebola therapies

Experimental Ebola treatments are to be reviewed by the European Medicines Agency as part of the international response to the disease outbreak in West Africa.…

Patients to get a voice in European Medicines Agency pilot

For the first time patients will be invited to give their views on the benefits and risks of some medicines in meetings with the European Medicines Agency’s Committee for Medicinal Products for Human Use.…

Clinical Pharmacist’s monthly news round-up: the top 10 in September 2014

What has been happening in the world of pharmacy? Here’s our pick of must-read news from the past month……

OTC domperidone will be missed

The antiemetic domperidone’s reclassification shows the importance of pharmacovigilance, but the loss of such a useful over-the-counter medicine ought to have been better communicated to community pharmacies.…

New antibiotic for hospital-acquired pneumonia now available in Europe

The antibiotic telavancin (Vibativ) has been made available in Europe for the treatment of adults who have contracted pneumonia in hospital, including ventilator associated pneumonia, caused by meticillin-resistant Staphylococcus aureus.…

Role for smartphones and social media in medicine safety

An app will be developed to make it easy for healthcare professionals and the public to report suspected adverse drug reactions.…

Ten-year study by Takeda calls into question pioglitazone’s link with bladder cancer

Use of the diabetes drug pioglitazone is not associated with an increased risk of bladder cancer, the drug’s manufacturer Takeda has claimed.…